![mymind protocol mymind protocol](https://mymind.org/image/posts/5c6a5fa0-c14b-4238-9283-2d4ce01f4563.png)
8–11 Stimulants such as methylphenidate are widely prescribed to regulate the associated brain functions and to control symptoms associated ADHD.
![mymind protocol mymind protocol](https://i.ytimg.com/vi/yYAI0MIaK60/maxresdefault.jpg)
Individuals with ADHD have abnormalities in the right prefrontal region, the basal ganglia and the cerebellum, as well as dysfunction in neurotransmitter, such as norepinephrine and dopamine. Pharmacological intervention is widely used as the main treatment option in view of the neurobiological nature of ADHD. The annual cost in USA of ADHD was estimated at between $36 billion and $52 billion in 2005. 6 All these problems associated with ADHD cast a significant economic cost to society.
![mymind protocol mymind protocol](https://s3.amazonaws.com/xmindshare/preview/KrWh-NFgOhUt-41351.png)
5 Moreover, comorbid mental health problems are common among individuals with ADHD, such as disruptive mood dysregulation disorder, anxiety disorders, major depressive disorder, obsessive-compulsive disorder and substance use disorder.
![mymind protocol mymind protocol](http://3.bp.blogspot.com/_pGpANSF8r0s/S8C93u5CvHI/AAAAAAAACWQ/MCzL5pH8ovk/s400/MFTH+protocol+2+pp.jpg)
5 They experience poorer academic achievements, poorer peer relationships, lack of constructive leisure activities, higher rates of job turnover, as well as higher rates of emergency room visits and automobile accidents as compared with their age-mates. 4 The core symptoms of inattention, hyperactivity and impulsivity are associated with different pervasive functional problems among individuals with ADHD. 3 ADHD is regarded as a costly public health problem. 2 In Hong Kong, the prevalence was found to be 3.9% among high school students aged 13.8 years. 1 A study published in 2015 showed that the global prevalence was found to be 3.4%. The effects of intervention will be evaluated by comparing outcomes between the two arms, as well as comparing outcomes within subject through comparing measurements at baseline (T0), immediately after the 8 week intervention (T1) and at 3 (T2) and 6 (T3) months postintervention.Īttention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental childhood disorder. Parents’ parental stress, parenting styles, ADHD related symptoms, well-being, rumination level and mindfulness levels will also be measured. The primary and secondary outcomes will include children’s attention, ADHD-related symptoms, behaviours, executive function and mindfulness levels measured by validated objective measures and parent’s reported instruments. The intervention includes 8 weekly 90 min group sessions for children with ADHD (aged 8–12 years) and their respective parents. These families will be randomised into intervention group (n=70) who will be offered the MYmind programme delivered by trained healthcare professionals, and an active control group (n=70) who will be offered the CBT programme.
#Mymind protocol trial
Methods and analysis This study will adopt a randomised controlled trial design including 140 children aged 8–12 years with ADHD together with one of their parents (n=140).